Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide (Q33276804)

25 July 2017

Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide (English)

1 reference

Clostridioides difficile colitis

25 July 2017

Clostridium difficile

0 references

1 reference

1 reference

Daniel M Musher

1

1 reference

25 July 2017

Nancy Logan

2

1 reference

25 July 2017

Vaibhav Mehendiratta

3

1 reference

25 July 2017

Nicolas A Melgarejo

4

1 reference

25 July 2017

Sagar Garud

5

1 reference

25 July 2017

Richard J Hamill

6

1 reference

25 July 2017

language of work or name

English

0 references

publication date

2 March 2007

1 reference

Journal of Antimicrobial Chemotherapy

25 July 2017

1 reference

25 July 2017

59

1 reference

25 July 2017

4

1 reference

25 July 2017

705-710

1 reference

Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

25 July 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Treatment of Clostridium difficile colitis and diarrhea with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Treatment of Clostridium difficile-associated disease: old therapies and new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Nitazoxanide: a new broad spectrum antiparasitic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Nitazoxanide: a new thiazolide antiparasitic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Nitazoxanide for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

An epidemic, toxin gene-variant strain of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Clostridium difficile infection in patients with unexplained leukocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL553

21 January 2018

Identifiers

DOI

10.1093/JAC/DKL553

1 reference

25 July 2017

1 reference